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Abstract
Dyslipidemia is a well-established risk factor for coronary artery disease. However, the effect on cerebral artery disease, and more
specifically the rupture risk of intracranial aneurysms, is unclear and has not yet been reviewed. We therefore performed a
systematic review to investigate associations between different types of dyslipidemia and incidence of aneurysmal subarachnoid
hemorrhage (aSAH).We used theMEDLINE, Embase, andWeb of Science databases to identify clinical trials that compared the
rupture risk among SAH patients with or without dyslipidemia. The risk of bias in each included study was evaluated using the
Critical Appraisal Skills Program (CASP). Of 149 unique citations from the initial literature search, five clinical trials with a case-
control design met our eligibility criteria. These studies compared aSAH patients to patients with unruptured aneurysms and
found an overall inverse relationship between hypercholesterolemia and rupture risk of intracranial aneurysms. The quality
assessment classified all included studies as high risk of bias. The evidence indicates that hypercholesterolemia is associated
with a reduced rupture risk of intracranial aneurysms. However, it is not clear whether this relation is due to the dyslipidemic
condition itself or the use of antihyperlipidemic medication.
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Introduction
The prevalence of intracranial aneurysms (IA) in the general
population is estimated to be 1–2%, whereas the annual inci-
dence of aneurysmal subarachnoid hemorrhage (aSAH) is es-
timated at around 1/10,000 in Norway [27, 41]. aSAH is a life-
threatening condition with mortality rates as high as 35%, and
a significant morbidity in survivors. For a long time, the re-
search on SAH was mostly focused on treatment options and
outcomes, but for the last 20 years, risk factors like age, sex,
hypertension, aneurysm size, and smoking have been
established [17]. However, the etiology of aSAH and more
specifically the rupture risk of intracranial aneurysms are not
fully understood.
Dyslipidemia is a well-established risk factor for develop-
ing coronary artery disease (CAD) [15]. The term dyslipid-
emia covers a broad spectrum of lipid abnormalities. Studies
have shown that elevated levels of total cholesterol (TC) and
low-density lipoprotein cholesterol (LDL-C) are associated
with cardiovascular events [13]. Increased very-low-density
lipoprotein (VLDL) remnants, reflected by elevated triglycer-
ides (TGs), increased small, dense low-density lipoprotein
(sdLDL) particles, and reduced high-density lipoprotein cho-
lesterol (HDL-C) levels, are termed the atherogenic lipid triad
and are more common than other pathological patterns [11].
Several risk factors for CAD, such as hypertension
and smoking, have been associated with the develop-
ment and risk of rupture of an intracranial aneurysm
[4, 17]. Except for a family history of aSAH, these
cardiovascular risk factors have the highest population-
attributable risk associated with aSAH [36].
However, hypercholesterolemia was associated with a
seemingly paradoxical 40% reduction in the risk of aSAH in
a review of case-control studies [12]. Furthermore, a recent
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systematic review on obesity and aSAH indicated a reduced
risk of aneurysm rupture with increasing BMI but concluded
that this seemingly paradoxical relation remains to be studied
in more detail [33]. The same group performed a systematic
review on cholesterol as a risk factor for aSAH and concluded
that elevated TC levels increased the risk of aSAH amongmen
[26]. No other systematic reviews or meta-analyses have in-
vestigated the relationship between dyslipidemia and the risk
of intracranial aneurysmal rupture causing aSAH.
In this review, we aimed to explore associations between
different types of dyslipidemia (high levels of TC, high levels
of LDL-C, low levels of HDL-C, and/or high levels of TGs)
and the rupture risk of intracranial aneurysms, searching for
studies comparing patients with unruptured intracranial aneu-
rysms (UIA) to patients with aSAH.
Over the last 30 years, the use of statins and other lipid-
lowering drugs in the treatment of dyslipidemia has increased
rapidly, and investigating dyslipidemia separately without the
impact of statins is challenging [37]. Therefore, we also consid-
ered the effect of statin use on the risk of aneurysmal rupture.
Materials and methods
Literature searches and study selection
The PRISMA guidelines 2020 [32] have been guiding this
systematic review, and we used the PICO framework to for-
mulate the study question and identify selection criteria of
eligible studies:
P (population/patients): A case group of adults with
aSAH and a control group of adults with confirmed UIA
I (intervention or exposure; treatment, diagnosis, or ob-
servation): Adults with aSAH and dyslipidemia
C (comparison/control): Adults with aSAH without
dyslipidemia
O (outcome): Rupture risk reported as odds ratio (OR),
hazard ratio (HR), or risk ratio (RR) when comparing the
incidence of aSAH among patients with and without
dyslipidemia
One investigator (KL) conducted systematic literature
searches of the PubMed (https://pubmed.ncbi.nlm.nih.gov),
Embase (http://www.embase.com), and Web of Science
(https://clarivate.com/products/web-of-science) databases up
to March 3, 2020.
The PICO process resulted in the following search strings:
PubMed: (subarachnoid hemorrhage[MeSH Terms] OR
int racran ia l aneurysms[MeSH Terms]) AND
( d y s l i p i d e m i a s [ M e S H T e r m s ] O R
hypercholesterolemia[MeSH Terms]).
Embase: dyslipidemia AND (subarachnoid hemorrhage
OR intracranial aneurysm)—limit searches to “full text,”
“human,” “english.”
Web of Science: (TS=((subarachnoid hemorrhage OR
intracranial aneurysm) AND (dyslipidemias OR hyper-
cholesterolemia))) AND LANGUAGE: (English).
Case reports, case series, letters, commentaries, book chapters,
animal studies, and descriptive studies without calculated risk
estimates (HR, OR, or RR) were excluded, as well as studies
on children and articles written in languages other than English.
Titles and abstracts of all retrieved articles from the primary
search were reviewed to identify eligible studies, and the full-
text version of these was then read and assessed before the
final inclusion according to the PICO criteria. In addition,
manual searches of the references from selected original re-
search and review articles were conducted.
Data extraction and quality assessment
We chose the Critical Appraisal Skills Program (CASP) to
evaluate the research methods of previous studies [5]. Using
the checklists, we categorized the studies into low, unclear, or
high risk of bias based on domains we considered being the
most important to evaluate study biases and methodological
shortcomings. These are the five domains we chose:
1. Sudden-death aSAH: When using hospital-based regis-
ters, a selection bias may occur if aSAH patients who
die before hospital admittance are not included in the
study. The risk factor status in these patients is as impor-
tant as in those hospitalized, and substantial data is lost
when excluding these patients. Inclusion of sudden-death
aSAH was thus required to reach low risk of bias.
2. Sufficient sample size: The impact of dyslipidemia on
rupture risk of intracranial aneurysms is not confirmed.
To obtain statistically significant results, the number of
patients included in a study matters. To calculate a suffi-
cient sample size, we used a Z-score of 1.96 (correspond-
ing to a 95% confidence interval [CI]), a standard devia-
tion (SD) of 0.5, a margin of error of 5% and the following
formula [8]:
(Z-score)2 * SD * (1−SD) / (margin of error)2
This resulted in a sample size of at least 385 patients.
3. Controlling for treatment of dyslipidemia: An unsolved
question is whether an association between dyslipidemia
and aneurysmal rupture risk is related to the condition of
dyslipidemia per se or is due to treatment effects of lipid-
lowering drugs. Therefore, to reach low risk of bias, the
studies had to control for the use of statins and/or other
medications in the statistical analyses, as far as possible,
and to consider the contribution of treatment effects when
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discussing the relationship between dyslipidemia and rup-
ture risk.
4. Confirmation of aneurysmal presence: The method of
confirming that the intracranial hemorrhage was actually
related to a ruptured aneurysm was chosen as a domain
where possible bias could occur, as paroxysmal or trau-
matic SAH would provide wrong results when studying
rupture risk. CT angiography, MRI with MR-angiogra-
phy, or conventional angiography performed by an expe-
rienced radiologist was required to reach low risk of bias.
5. History of ruptured aneurysms: A previous incidence of
aneurysmal rupture increases the risk of new ruptures.
Therefore, patients with a history of any intracranial hem-
orrhage both in the UIA and aSAH group should be ex-
cluded to reach low risk of bias.
Results
Study selection
A flowchart of the evaluated studies in this review is presented
in Fig. 1. From 149 unique citations in the initial search, 111
articles were excluded after reviewing titles and abstracts. The
remaining 38 studies considered relevant were then assessed
in full text. Of these, five articles met the eligibility criteria and
were included in the review [19, 22, 28, 42, 44].
Furthermore, we found six studies that were categorized as
“near-misses,” i.e., considered relevant but did not meet all
inclusion criteria [12, 21, 25, 29, 39, 40]. This was mainly
due to the study design, meaning that they did not compare
aSAH cases with UIA controls, but only investigated lipids as
risk factors for aSAH, as in a previous systematic review [26].
From the reference lists of the five included studies, no other
eligible articles were found.
Study characteristics
All included studies had a case-control design [19, 22, 28, 42,
44], and compared aSAH patients to unmatched UIA controls
in three different countries (Table 1).
One of these studies investigated only the rupture risk of a
specific anatomic aneurysm location (anterior communicating
artery) [28]. The results of the multivariable analyses from the
five studies are presented in Fig 2.
Study 1
In a hospital-based case-control study in Japan, which inves-
tigated statin use as the primary exposure of interest,
Yoshimura et al. showed that use of any statin was inversely
associated with cerebral aneurysm rupture (OR 0.30, 95% CI
0.12–0.65) when controlling for sex, age, hypertension, serum
TC, smoking, and alcohol consumption. [44]. The study pop-
ulation included 117 cases of patients with aSAH and 304
controls selected from patients with a newly diagnosed,
unruptured aneurysm. In a stratified analysis by serum TC,
the authors observed that statin use was inversely associated
with cerebral aneurysm rupture regardless of serum cholester-
ol level in participants with 130–219 mg/dL (OR 0.21, 95%
CI 0.08–0.55) and 220 mg/dL or more (OR 0.43, 95% CI
0.09–2.10), also when adjusting for sex, age, hypertension,
smoking, and alcohol consumption.
Study 2
In a case-control study from the Netherlands, Vlak et al. found
a decreased risk of rupture with hypercholesterolemia when
studying 250 patients with aSAH compared to 206 patients
with UIA in a univariable analysis (OR 0.3, 95% CI 0.1–0.5),
as well as in a multivariable analysis including smoking, pre-
vious stroke, migraine, and a family history of aSAH (OR 0.4,
95% CI 0.2–1.0) [42]. Data from the questionnaire were in-
sufficient to conclude whether hypercholesterolemia or its
treatment with statins exerted a risk-reducing effect.
Study 3
Matsukawa et al. studied specifically the rupture of anterior
communicating artery (ACOM) aneurysms in a case-control
study including 78 patients with aSAH and 62 patients with
UIA [28]. Hypercholesterolemia was defined as taking
antihyperlipidemic agents or having a TC level of >220 mg/
dL (>5.7 mmol/L). The study found that hypercholesterolemia
was significantly more common in the control group with UIA
compared to the aSAH patients using the Student t-test (P =
0.0092), but this relationship was not significant in a multi-
variable logistic regression (OR 0.32, 95% CI 0.076–1.3) with
covariates including age < 60 years, current smoking, anterior
and lateral dome direction, bleb, aneurysm size >5 mm, and
another unruptured aneurysm.
Study 4
Another Japanese study conducted by Inagawa et al. in
Shimane City included 858 patients with ruptured aneurysms,
285 patients with UIA (and no history of aSAH), and 798
healthy control subjects [22]. They found that hypercholester-
olemia was strongly associated with a decreased risk of rup-
ture, regardless of age and sex (OR 0.45, 95% CI 0.33–0.61).
Hypercholesterolemia was also significantly more common in
patients with UIA than in controls. aSAH was confirmed by
CT scan, surgery, and/or autopsy. Hypercholesterolemia was
considered present when the serum TC level was 220 mg/dL
(5.7 mmol/L) or higher, and/or if patients were being treated
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with lipid-lowering medications such as statins. They did not
report results frommodels controlling for drug use. Therefore,
the impact of statins is unknown.
Study 5
Hostettler et al. compared patients from 22 UK hospitals, in-
cluding 605 patients with UIA and 1729 patients with aSAH
over a 3-year period [19]. Hypercholesterolemia was found to
be inversely associated with aSAH in the univariable analysis
(OR 0.45, 95% CI 0.37–0.55, P < 0.001), and in the multivar-
iable analysis including age, sex, ethnicity, smoking, antihy-
pertensive medication, aspirin use, aneurysm location, and
aneurysm size as covariates, and independently of statin use
(OR 0.64, 95% CI 0.48–0.85, P = 0.002).
Risk of bias and quality assessments
None of the studies comparing UIA to aSAH [19, 22, 28, 42,
44] fulfilled the criteria for low risk of bias classification in all
Fig. 1 Flowchart of the literature
searches and study selection. P,




aneurysms; OR, odds ratio; HR,
hazard ratio; RR, relative risk.
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based on the PRISMA flow
diagram. Moher et al. [46]
Table 1 Study characteristics
















Yoshimura [44] Japan 2014 Case-control 117 304 60.5 64,3 35 34.2 Statin use and hyperlipidemia in
medical records
Vlak [42] Netherlands 2013 Case-control 250 206 54.7 54.6 24.8 33 Diagnosis of
hypercholesterolemia in
medical records
Matsukawa [28] Japan 2013 Case-control 78 62 58 63 34 31 TC >220 mg/dL and/or use of
lipid-lowering medicaments
Inagawa [22] Japan 2010 Case-control 858 798 64.0 65.9 34.6 34.6 TC >220 mg/dL and/or use of
lipid-lowering medicaments
Hostettler [19] UK 2018 Case-control 1729 605 53.2 57.0 29.7 29.8 Statin use and
hypercholesterolemia in
medical records
aSAH, aneurysmal subarachnoid hemorrhage; UIA, unruptured intracranial aneurysm; TC, total cholesterol
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of the chosen domains (Table 2). Thus, all five studies were
overall classified as high risk of bias.
Discussion
The five studies which compared UIA patients to aSAH pa-
tients found a statistically significant paradoxical relation be-
tween hypercholesterolemia and risk of aneurysmal rupture.
Although one study was able to adjust for statin use, it is not
clear whether the protective effect derives from the hypercho-
lesterolemia itself, or the use of statin therapy.
A protective effect of hypercholesterolemia could partly
emerge through stabilization of the aneurysm wall by forma-
tion of hard atherosclerotic plaque, and further preventing a
newly formed aneurysm from rupture [19].
The traditional “diet heart” or lipid hypothesis consists of
three main statements: (1) higher intakes of saturated fatty
acids (SFAs) raise circulating levels of TC and LDL-C, (2)
elevated blood levels of cholesterol lead to atherosclerosis and
cardiovascular disease (CVD), and consequently (3) a diet
rich in SFAs promotes atherosclerosis and increases the risk
of CVD. This hypothesis has in the last 20 years been criti-
cized and challenged by contradictory studies showing that
cholesterol-lowering did not prevent CVD and that reduced
intakes of dietary SFAs have not been consistently associated
with reduced CVD events or mortality [2, 6, 7, 9, 18, 24, 30,
34, 45].
The most common cholesterol-lowering drugs are statins,
and the number of patients on statin therapy is increasing.
Statins reduce atherogenic lipoproteins, reduce C-reactive
protein levels, and thereby have an anti-inflammatory effect
which may be beneficial for the stabilization of the aneurysm
wall [16]. It is also important to consider the side effects of
statins in multiple organ systems, such as muscular problems,
mental and neurological symptoms, liver damage, and renal
failure [35]. Recent literature has suggested statin therapy in
the progression of abdominal aortic aneurysmal disease, after
animal studies showing a reduction in aortic diameter and the
incidence of aneurysms [3, 38]. A future possible recommen-
dation of statin prophylaxis in patients with high risk of aSAH
should therefore be discussed with caution.
Limitations and strengths in the reviewed studies
The main limitation in the reviewed studies, which is also
relevant for the possible clinical relevance of the results, is
the effect of statin use in the patients studied. If the use of
statins exerts the apparent protective effect of dyslipidemia,
this demands a different approach.
Considering the origin of the studies, three of them derived
from Japan, which may reflect ethnic differences in the patient
population given that recent genetic analyses have suggested
that Japanese (and/or Finnish) patients are at higher risk for
aneurysm rupture [20].
The authors of all five studies discussed the possibility of a
selection bias, especially in the UIA group, due to the fact that
a family history of aSAH is more likely to undergo brain
imaging.







Fig. 2 Forest plot of odds ratios (OR) from multivariable analyses.
Yoshimura et al. adjusted for sex, age, hypertension, serum TC, smoking,
and alcohol consumption. Vlak et al. adjusted for smoking, previous
stroke, migraine, and a family history of aSAH.Matsukawa et al. adjusted
for age, smoking, anterior and lateral dome direction of aneurysm, bleb,
aneurysm size, and other unruptured aneurysm. Inagawa et al. adjusted
for age and sex. Hostettler et al. adjusted for age, sex, ethnicity, smoking,
aneurysm location, aneurysm size, and drug use including
antihypertensiva, aspirin, and statin. Made by K. Løvik in Microsoft
Excel, © 2021 Microsoft
Table 2 Risk of bias









Yoshimura [44] − + + + + High
Vlak [42] − + − + + High
Matsukawa [28] − − − + + High
Inagawa [22] NA + − + + High
Hostettler [19] − + + + + High
+ low risk of bias;− high risk of bias; NA (not applicable), unclear risk of bias; aSAH, aneurysmal subarachnoid hemorrhage
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Considering sample sizes, two of the studies included large
patient groups [19, 22], and one study had a sample size too
small to be considered as low risk of bias [28]. Two studies
have patient numbers within the low risk of bias classification,
but still relatively small. The inclusion phase was, respective-
ly, 5 years (2 years for the aSAH group) in one study [44] and
3 years in another study [42]. This may be explained by the
decreasing incidence of aSAHworldwide, partially due to less
smoking and lower blood pressure [10].
In the study by Yoshimura et al. (study 1), the primary
exposure of interest was statin use [44]. They found that high
cholesterol levels were protective against cerebral aneurysm
rupture and that statins appeared to be protective against ce-
rebral aneurysm rupture in high and normal cholesterol-level
groups. An important limitation in this study was that they did
not analyze serum lipids before and after statin administration
to verify the effects of statins, but, regardless of serum choles-
terol levels, statin use was inversely associated with the oc-
currence of aneurysmal rupture. The authors discussed that it
remains uncertain whether statins are beneficial for the pre-
vention of aSAH and requested further and larger studies to
confirm their findings and safety of statins in aSAH preven-
tion. The number of patients was within our classification of
low risk of bias.
Vlak et al. (study 2) did not register the use of statins [42].
Whether the observed reduction of risk of rupture was caused
by the use of statins or by the hypercholesterolemia itself is
therefore unknown. The authors suggested that if the risk de-
creasing effect of hypercholesterolemia was mediated by stat-
in use, statins might be an additional treatment option for
decreasing the rupture risk of UIA. They also discussed the
possible difficulties of performing a prospective study on the
influence of drugs on the rupture risk, which would need a
very long-term follow-up.
Matsukawa et al. (study 3) and Inagawa et al. (study 4) both
defined hypercholesterolemia as taking antihyperlipidemic
agents and/or having a TC level of >220 mg/dL [22, 28].
They were not able to correct for statin use, and the origin of
the protective effect is unknown.
The study by Matsukawa and co-workers was conducted
retrospectively at a single institution, with a patient number
too small to draw definite conclusions [28]. Furthermore, they
only studied anterior communicating artery (ACOM) aneu-
rysms. This location has a significantly higher rupture rate
than other anterior circulation aneurysms, where common an-
atomical variations such as unilateral A1 hypoplasia (or
aplasia) further predisposes ACOM aneurysms to rupture.
Thus, the results from this study may not be representative
of aSAH risk in general [1]. Although the study found a re-
duced risk of rupture among patients with hypercholesterol-
emia, the authors did not suggest clinical implications or fur-
ther studies on the topic, probably because the study was
mainly focused on aneurysm characteristics.
Inagawa et al. proposed that hypercholesterolemia
may contribute to aneurysm formation, whereas it may
reduce the risk of aneurysm rupture [22]. Thus, they
highlighted the important point that the risk factors for
aneurysm formation and rupture may not necessarily
be the same.
The British study from Hostettler et al. (study 5) recorded
both statin use and a diagnosis of hyperlipidemia [19]. They
found hypercholesterolemia to be inversely associated with
risk of aneurysmal rupture, independent of statin treatment.
The authors suggested that part of the effect could emerge
through stabilization of the aneurysmwall, preventing a newly
formed aneurysm from rupturing. The main focus of the con-
clusion was the effect of aspirin use on prevention of aSAH,
and the possible clinical implications regarding statins were
not further discussed.
Confounders in the reviewed studies
Themain confounding factor in the reviewed studies is the use
of statins and whether the apparent protective effect derives
from this or the actual dyslipidemia.
The anti-inflammatory and antioxidant effect of statins may
cause a profitable effect in patients with intracranial aneu-
rysms. Lipid accumulation is known to occur in the wall of
cerebral aneurysms, and this mechanism has been proposed as
a component in aneurysm wall pathogenesis as it is in the
pathophysiology of an atherosclerotic plaque [14, 23, 31].
The five reviewed studies have, to our knowledge, consid-
ered the most relevant risk factors in their statistical analyses.
It is still possible that other less established or unknown fac-
tors may have affected the results, such as anthropometric
variables like body mass index (BMI) and body fat percent,
the concentrations of different lipoprotein particle subclasses,
and apolipoproteins, but the study designs have not allowed a
further investigation thereof.
Conclusions
We were able to identify five studies investigating the associ-
ation of dyslipidemia and the risk of aneurysmal rupture,
which all described an inverse association when comparing
aSAH patients to a control group with UIA. Whether this
effect is due to dyslipidemia or medication for this condition
is not fully understood, but one study found a protective effect
independent of antihyperlipidemic agents [19].
Our assessment on risk of bias defined all five studies as
low quality. Inclusion of sudden-death aSAH patients is a
practical challenge and perhaps unrealistic to expect.
Without this criterion, two studies would qualify as low risk
of bias. Since all five studies describe a possible protective
effect of dyslipidemia on aneurysmal rupture and discuss their
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results with caution, we consider the results relevant for future
research and clinical treatment of UIA.We believe this review
raises new important questions to be answered in further stud-
ies. Ideally, it would be interesting to study patients with dys-
lipidemia without use of statins, but this is practically and
ethically difficult due to the globally increasing use of statin
therapy [43]. Another suggestion is to perform a prospective
study treating patients with established intracranial aneurysms
with statin therapy and follow the risk of rupture.
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